What are the qualifications and contraindications for transcatheter aortic valve replacement (TAVR) and why?

TAVR Qualifications and Contraindications

TAVR is recommended for patients with severe, symptomatic aortic stenosis who have suitable anatomy and predicted survival >12 months, with specific age and risk-based criteria determining whether TAVR or surgical AVR is preferred. 1, 2

Qualifications for TAVR

Disease Severity Requirements

Patients must have severe aortic stenosis defined by:

• Aortic jet velocity ≥4.0 m/s, OR
• Aortic valve area (AVA) ≤1.0 cm², OR
• AV index ≤0.6 cm²/m², OR
• Mean gradient ≥40 mm Hg
• Plus severely reduced, calcified leaflet motion 1

In patients with LV systolic dysfunction, dobutamine stress echo must demonstrate these same hemodynamic criteria at any flow rate 1.

Age and Risk-Based Selection Algorithm

For patients <65 years or life expectancy >20 years:

• SAVR is recommended (not TAVR) 2
• Why: Unknown long-term TAVR durability makes surgery preferable when decades of valve function are needed

For patients 65-80 years:

• Either SAVR or transfemoral TAVR is appropriate 2
• Decision requires shared decision-making balancing patient longevity vs. valve durability
• Why: Randomized trials show equivalent outcomes in this age range with current-generation devices

For patients >80 years or life expectancy <10 years:

• Transfemoral TAVR is preferred over SAVR 2
• Why: Lower procedural morbidity outweighs durability concerns given limited life expectancy

For prohibitive surgical risk (any age):

• TAVR is recommended if post-procedure survival expected >12 months with acceptable quality of life 1
• Prohibitive risk = ≥50% estimated 30-day mortality/irreversible morbidity, OR factors like frailty, porcelain aorta, prior chest radiation, severe hepatic/pulmonary disease 1

Anatomic Requirements

Aortic annulus sizing:

• Balloon-expandable devices: 18-25 mm 3
• Self-expandable devices: 20-27 mm 3
• Why: Incorrect sizing causes paravalvular leak or valve migration

Vascular access:

• Adequate iliofemoral vessels (≥6-9 mm diameter depending on device) 3
• Alternative access (subclavian, axillary, transapical, direct aortic) if transfemoral unsuitable 1
• Why: Catheter systems are 14-24 Fr; inadequate vessels cause vascular complications

Coronary clearance:

• Sufficient distance from valve plane to coronary ostia 1
• Why: Prevents coronary occlusion during valve deployment

Absolute Contraindications

Anatomic Contraindications

• Bicuspid aortic valve 1

  • Why: Asymmetric anatomy causes incomplete valve deployment and higher paravalvular leak rates

• Annulus outside device size range (see above) 3

  • Why: No appropriately sized device available

• LV apical thrombus 3

  • Why: Embolic risk during transapical access

• Asymmetric heavy valvular calcification that may compress coronary arteries 3

  • Why: Risk of coronary occlusion during valve expansion

• Aortic root <45 mm at sinotubular junction (for self-expandable devices) 3

  • Why: Inadequate anchoring and valve migration risk

Vascular Contraindications (for transfemoral approach)

• Severe iliofemoral calcification, tortuosity, or small diameter 3
• Severe aortic arch atheroma or angulation 3
• Abdominal aortic aneurysm with protruding thrombus 3
• Previous aortofemoral bypass 3
• Why: These increase stroke, vascular injury, and access failure rates

Clinical Contraindications

• Life expectancy <12 months despite TAVR 4, 1

  • Why: Procedure offers no meaningful survival or quality-of-life benefit; represents futility

• No expected quality-of-life improvement 4, 2

  • Why: 21% of TAVR patients experience functional decline at 6 months; frailty indices predict poor outcomes 4

• Active endocarditis 4

  • Why: Infection risk on prosthetic material

Relative Contraindications (Insufficient Data)

TAVR is not currently recommended in these scenarios due to limited evidence 1:

• Acceptable/low surgical risk (now evolving with recent trials)
• Failing bioprosthetic valve (valve-in-valve now more established)
• Severe mitral regurgitation or severe mitral annular calcification
• Moderate (non-severe) aortic stenosis
• Pure aortic regurgitation without stenosis
• Subaortic stenosis

Critical Screening Requirements

Every TAVR candidate requires 1:

• STS risk score calculation
• Multidisciplinary heart team evaluation (cardiologist, 2 cardiac surgeons minimum)
• High-quality CT angiography for annular sizing and vascular assessment 5, 6
• Echocardiography confirming AS severity and excluding other significant valve disease
• Coronary angiography to identify revascularization needs 3
• Frailty assessment (cognition, mobility, nutrition, activities of daily living) 4

Common Pitfalls to Avoid

1. Using TAVR in patients who won't benefit functionally - Assess frailty and realistic functional recovery potential, not just survival 4, 7

2. Inadequate anatomic assessment - CT angiography is mandatory; echocardiography alone underestimates annular size 5, 6

3. Ignoring life expectancy - A patient may survive the procedure but die from comorbidities within months, making TAVR futile 4, 7

4. Proceeding without heart team consensus - Requires input from cardiology, cardiac surgery, imaging, and often geriatrics 1, 4

5. Applying TAVR to younger patients without considering durability - Long-term valve performance beyond 10 years remains uncertain 2, 8